106 related articles for article (PubMed ID: 1721307)
1. In vitro assessment of FK 506 immunosuppressive activity in transplant patients.
Zeevi A; Venkataramanan R; Warty V; Eiras G; Woan M; Abu-Elmagd K; Alessiani M; Jain A; Demetris AJ; Zerbe T
Transplant Proc; 1991 Dec; 23(6):2897-9. PubMed ID: 1721307
[No Abstract] [Full Text] [Related]
2. Comparison of plasma vs whole blood as matrix for FK 506 drug level monitoring.
Winkler M; Wonigeit K; Undre N; Ringe B; Oldhafer K; Christians U; Pichlmayr R
Transplant Proc; 1995 Feb; 27(1):822-5. PubMed ID: 7533433
[No Abstract] [Full Text] [Related]
3. Therapeutic monitoring of tacrolimus concentrations in blood of renal and liver transplant recipients: comparison of microparticle enzyme immunoassay and enzyme multiplied immunoassay methods.
Bartlomiejczyk I; Zochowska D; Sanko-Resmer J; Matuszewicz D; Paczek L
Transplant Proc; 2006; 38(1):94-6. PubMed ID: 16504673
[TBL] [Abstract][Full Text] [Related]
4. Specificity of therapeutic drug monitoring of tacrolimus in kidney transplant patients.
Sato S; Fuchinoue S; Tojimbara T; Fujita S; Nakajima I; Agishi T; Hayashi T; Teramura Y; Fujita E; Iwasaki K
Transplant Proc; 1998 Jun; 30(4):1274-5. PubMed ID: 9636517
[No Abstract] [Full Text] [Related]
5. Clinical relevance of monitoring tacrolimus: comparison of microparticle enzyme immunoassay, enzyme-linked immunosorbent assay, and liquid chromatography mass spectrometry in renal transplant recipients converted from cyclosporine to tacrolimus.
Braun F; Lorf T; Schütz E; Christians U; Grupp C; Sattler B; Canelo R; Sewing KF; Armstrong VW; Oellerich M; Ringe B
Transplant Proc; 1996 Dec; 28(6):3175-6. PubMed ID: 8962231
[No Abstract] [Full Text] [Related]
6. Phase III study of FK 506 in kidney transplantation. Japanese FK 506 Study Group.
Ochiai T; Fukao K; Takahashi K; Endo T; Oshima S; Uchida K; Yokoyama I; Ishibashi M; Takahara S; Iwasaki Y
Transplant Proc; 1995 Feb; 27(1):829-33. PubMed ID: 7533435
[No Abstract] [Full Text] [Related]
7. Evaluation of the new EMIT tacrolimus assay in kidney and liver transplant recipients.
Akbas SH; Yavuz A; Tuncer M; Yurdakonar E; Akcit F; Gurkan A; Demirbas A; Gultekin M; Ersoy F; Akaydin M
Transplant Proc; 2004; 36(1):86-8. PubMed ID: 15013308
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of FK 506 blood levels in kidney transplant recipients.
Takahara S; Kokado Y; Kameoka H; Takano Y; Jiang H; Moutabarrik A; Ishibashi M; Okuyama A; Sonoda T
Transplant Proc; 1994 Aug; 26(4):2106-8. PubMed ID: 7520623
[No Abstract] [Full Text] [Related]
9. Therapeutic monitoring of tacrolimus in pediatric and adult transplanted patients.
Capone D; Gentile A; Vajro P; Stanziale P; Imperatore P; De Silva C; Pellegrino T; Basile V
J Chemother; 1998 Apr; 10(2):176-8. PubMed ID: 9603651
[No Abstract] [Full Text] [Related]
10. Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient.
Freise CE; Rowley H; Lake J; Hebert M; Ascher NL; Roberts JP
Transplant Proc; 1991 Dec; 23(6):3173-4. PubMed ID: 1721397
[No Abstract] [Full Text] [Related]
11. Strategy of FK 506 therapy in liver transplant patients: effect of graft function.
Abu-Elmagd KM; Fung JJ; Alessiani M; Jain A; Takaya S; Venkataramanan R; Warty VS; Shannon W; Todo S; Tzakis A
Transplant Proc; 1991 Dec; 23(6):2771-4. PubMed ID: 1721272
[No Abstract] [Full Text] [Related]
12. Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients.
Winkler M; Jost U; Ringe B; Gubernatis G; Wonigeit K; Pichlmayr R
Transplant Proc; 1991 Dec; 23(6):3153-5. PubMed ID: 1721389
[No Abstract] [Full Text] [Related]
13. Demographic considerations in tacrolimus pharmacokinetics.
Fitzsimmons WE; Bekersky I; Dressler D; Raye K; Hodosh E; Mekki Q
Transplant Proc; 1998 Jun; 30(4):1359-64. PubMed ID: 9636552
[No Abstract] [Full Text] [Related]
14. Failure of immunosuppressive drug levels to predict T-cell reactivity in pediatric transplant patients.
Sampson VB; Dunn SP; Rymeski B; Malatack J; Rong NH; Flynn L; Krueger LJ
J Pediatr Surg; 2008 Jun; 43(6):1134-41. PubMed ID: 18558196
[TBL] [Abstract][Full Text] [Related]
15. Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression.
Zeevi A; Eiras G; Burckart G; Jain A; Kragack A; Venkataramanan R; Todo S; Fung J; Starzl TE; Duquesnoy RJ
Transplant Proc; 1990 Feb; 22(1):60-3. PubMed ID: 1689902
[No Abstract] [Full Text] [Related]
16. Human islet allotransplantation under FK 506.
Ricordi C; Tzakis A; Carroll P; Zeng Y; Rilo HL; Alejandro R; Shapiro R; Fung JJ; Mintz DH; Starzl TE
Transplant Proc; 1991 Dec; 23(6):3207. PubMed ID: 1721410
[No Abstract] [Full Text] [Related]
17. Optimised first-line FK506-based protocols in liver transplantation: experience from the University Hospital Rudolf Virchow, Berlin.
Neuhaus PJ
Transplant Proc; 1994 Dec; 26(6):3264-6. PubMed ID: 7527961
[No Abstract] [Full Text] [Related]
18. Calcineurin Inhibitor Determination in Whole Blood With the RXL Dimension Analyzer: A Useful Tool for Immunosuppressive Drug Monitoring.
Ventura E; Bonardet A; Pageaux GP; Mourad G; Cristol JP
Transplant Proc; 2009 Mar; 41(2):707-9. PubMed ID: 19328963
[TBL] [Abstract][Full Text] [Related]
19. In vitro pentamer formation as a biomarker of tacrolimus-related immunosuppressive activity after liver transplantation.
Tolou-Ghamari Z; Wendon J; Tredger JM
Clin Chem Lab Med; 2000 Nov; 38(11):1209-11. PubMed ID: 11156362
[TBL] [Abstract][Full Text] [Related]
20. Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Japanese FK 506 Study Group.
Transplant Proc; 1991 Dec; 23(6):3085-8. PubMed ID: 1721367
[No Abstract] [Full Text] [Related]
[Next] [New Search]
